Franklin Genomic Financial Statements From 2010 to 2024
| HELX Etf | USD 29.53 0.29 0.99% |
Check Franklin Genomic financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Franklin Genomic's main balance sheet or income statement drivers, such as , as well as many indicators such as . Franklin financial statements analysis is a perfect complement when working with Franklin Genomic Valuation or Volatility modules.
Franklin |
Franklin Genomic Advancements ETF Beta Analysis
Franklin Genomic's Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Franklin Genomic Beta | 1.14 |
Most of Franklin Genomic's fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Franklin Genomic Advancements is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, Franklin Genomic Advancements has a Beta of 1.14. This is much higher than that of the Franklin Templeton Investments family and significantly higher than that of the Health category. The beta for all United States etfs is notably lower than that of the firm.
About Franklin Genomic Financial Statements
Franklin Genomic investors use historical fundamental indicators, such as Franklin Genomic's revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Franklin Genomic. Please read more on our technical analysis and fundamental analysis pages.
Under normal market conditions, the fund invests at least 80 percent of its net assets in equity securities of companies that are relevant to its investment theme of genomic advancements. Franklin Genomic is traded on BATS Exchange in the United States.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Franklin Genomic Adv offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Franklin Genomic's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Franklin Genomic Advancements Etf. Outlined below are crucial reports that will aid in making a well-informed decision on Franklin Genomic Advancements Etf:Check out the analysis of Franklin Genomic Correlation against competitors. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
The market value of Franklin Genomic Adv is measured differently than its book value, which is the value of Franklin that is recorded on the company's balance sheet. Investors also form their own opinion of Franklin Genomic's value that differs from its market value or its book value, called intrinsic value, which is Franklin Genomic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Franklin Genomic's market value can be influenced by many factors that don't directly affect Franklin Genomic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Franklin Genomic's value and its price as these two are different measures arrived at by different means. Investors typically determine if Franklin Genomic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Franklin Genomic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.